Date: 2016-05-19
Type of information: Establishment of a new subsidiary in the US
Compound:
Company: Enterome Bioscience (France)
Therapeutic area:
Type agreement: establishment of a new subsidiary in the US
Action mechanism:
Disease:
Details: * On May 19, 2016, Enterome Bioscience, a pioneer in the development of pharmaceuticals and diagnostics based on the gut microbiome, announced that it has opened a new office in Cambridge to support its operations and corporate development activities in the US. The office is located at Kendall Square, the heart of Boston’s booming biotechnology industry. The new office brings Enterome closer to its existing partners in the US and provides opportunities to reinforce and extend its scientific expertise and network to develop its business further. Rodolphe Clerval, Enterome’s Chief Business Officer, will head up the US office, and expects to expand the operation over the coming years. Enterome currently has partnerships with leading pharmaceutical companies and academic research institutes, including Johnson & Johnson Innovation/Janssen Biotech, Takeda and Abbvie in inflammatory bowel diseases; and the Mayo Clinic and Geisinger hospitals in metabolic disorders.
Financial terms:
Latest news:
